• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 26, 2016

View Archived Issues

Busy Denali Therapeutics inks potential $1B deal with F-star, raises $130M

LONDON – Neurodegenerative disease start-up Denali Therapeutics Inc. announced a slew of deals and collaborations, with a potential $1 billion agreement with bispecific antibody specialist F-star Ltd. heading the list. Read More

Novartis candidate slows progressive MS in phase III study

Novartis AG's siponimod (BAF312), a second-generation sphingosine 1-phosphate (S1P) receptor modulator designed to be more selective than Gilenya (fingolimod), reduced the risk of disability progression vs. placebo for people with secondary progressive multiple sclerosis (SPMS) during a large phase III study, the company reported. Regulatory filings seeking approval for the therapy are planned for 2019. Read More

FDA sieve stops Parsabiv; scarce Amgen CRL details but analysts eyeing safety

Amgen Inc.'s bid to get approved an I.V. replacement for its oral Sensipar hit choppy seas in the form of a complete response letter from the FDA on its PDUFA date regarding the NDA for Parsabiv (etelcalcetide), designed to treat secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis. Read More

Novan wades into IPO waters, seeks $60M for nitric oxide platform

Novan Inc. added its name to the IPO queue, revealing in an S-1 filing that it will seek to raise up to $60 million to advance its nitric oxide (NO) platform and programs in five dermatological conditions. The company plans to grant underwriters a 30-day option to purchase additional shares. Novan did not disclose the number of shares or price in its paperwork. Read More

In lungs, T cells err on side of caution in fighting tumor cells

The lungs are a frequent site of metastases in part because T cells sense oxygen levels and are more tolerant of foreign antigens in high-oxygen environments, scientists reported in the Aug. 25, 2016, advance online issue of Cell. Read More

Shenogen, Lee's partner to bring drug to China's liver cancer patients

Beijing Shenogen Pharma Group Ltd. has signed a co-development deal with Lee's Pharmaceutical Holdings Ltd., of Hong Kong, to combine Shenogen's lead compound, icaritin, a traditional Chinese medicine-derived small-molecule drug, with Pexa-Vec (JX-594, pexastimogene devacirepvec), an oncolytic virus being developed in China by Lee's. Read More

Big data, unchecked, could lead to personal data hijacking

To differentiate itself from competitors, a dating website has partnered with a big data genomics company to conduct proprietary and confidential research, gaining access to health data from millions of people. Customers submit their dream phenotypes, which are matched to digital genotypes, complete with names, addresses and an assortment of customized personal health data. Welcome to Matches Made in Heaven. Read More

Financings

Cesca Therapeutics Inc., of Rancho Cordova, Calif., said it converted a senior secured three-year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6.1 million shares of its common stock. Read More

Other news to note

Lion Biotechnologies Inc., of New York, said its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) was extended for an additional five-year term, to 2021. Read More

In the clinic

Armetheon Inc., of Milpitas, Calif., said data from a phase I trial of tecarfarin in severe chronic kidney (CKD) disease patients who require anticoagulation treatment showed good results. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe